A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries
- PMID: 32032639
- DOI: 10.1016/j.contraception.2020.01.011
A cross-sectional analysis of mifepristone, misoprostol, and combination mifepristone-misoprostol package inserts obtained in 20 countries
Abstract
Objectives: To evaluate the characteristics, clinical information, and storage instructions contained in package inserts from medical abortion commodities collected in low- and middle-income countries.
Study design: From November 2017 to February 2018 mifepristone, misoprostol, and combined mifepristone-misoprostol (combipack) products were collected to populate the Medical Abortion Commodities Database. We extracted stated indications for use, storage instructions, and date of last revision from each package insert obtained. For those inserts listing medical abortion as an indication, we also extracted eligibility criteria, recommended regimens, side effects, and contraindications.
Results: We identified 41 package inserts from 20 countries; 19 (46%) listed medical abortion as an indication including all 7 combipacks, all 7 mifepristone products, and 5/27 (19%) misoprostol products. Date of last insert revision ranged from 1991 to 2016. Gestational age limits for early medical abortion ranged from 49 days to "first trimester." Three (43%) mifepristone products recommended a 600 mg oral dose and two (29%) recommended regimens with gemeprost. Eighteen (67%) misoprostol and one (14%) combipack inserts recommended protection from moisture.
Conclusions: The characteristics, clinical information, and storage instructions in medical abortion product package inserts from a variety of field settings in low- and middle-income countries included inadequate storage instructions and outdated gestational age limits and regimens.
Implications: There is an urgent need to revisit approved inserts for medical abortion products in low- and middle-income countries to ensure information is accurate and reflects the current evidence base. Simultaneously, providing supplemental instructions targeted at users may fill some gaps. People have a right to accurate information to ensure a safe and effective medical abortion experience.
Keywords: Abortion; Medical abortion; Mifepristone; Misoprostol; Package insert.
Copyright © 2020 Elsevier Inc. All rights reserved.
Similar articles
-
Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion.Hum Reprod. 1995 Jun;10(6):1521-7. doi: 10.1093/humrep/10.6.1521. Hum Reprod. 1995. PMID: 7593528 Clinical Trial.
-
Systematic Review of the Effectiveness, Safety, and Acceptability of Mifepristone and Misoprostol for Medical Abortion in Low- and Middle-Income Countries.J Obstet Gynaecol Can. 2020 Dec;42(12):1532-1542.e2. doi: 10.1016/j.jogc.2020.04.006. Epub 2020 Apr 27. J Obstet Gynaecol Can. 2020. PMID: 32912726 Review.
-
Medical methods for first trimester abortion.Cochrane Database Syst Rev. 2004;(2):CD002855. doi: 10.1002/14651858.CD002855.pub3. Cochrane Database Syst Rev. 2004. PMID: 15106180 Updated. Review.
-
Medical methods for first trimester abortion.Cochrane Database Syst Rev. 2004;(1):CD002855. doi: 10.1002/14651858.CD002855.pub2. Cochrane Database Syst Rev. 2004. PMID: 14973995 Updated. Review.
-
Misoprostol is as effective as gemeprost in termination of second trimester pregnancy when combined with mifepristone: a randomised comparative trial.Contraception. 1996 May;53(5):281-3. Contraception. 1996. PMID: 8724617 Clinical Trial.
Cited by
-
Self-managed abortion: Exploring synergies between institutional medical systems and autonomous health movements.Contraception. 2021 Sep;104(3):219-221. doi: 10.1016/j.contraception.2021.06.006. Epub 2021 Jun 15. Contraception. 2021. PMID: 34139153 Free PMC article. No abstract available.
-
Self-managed abortion: a constellation of actors, a cacophony of laws?Sex Reprod Health Matters. 2021 Dec;29(1):1899764. doi: 10.1080/26410397.2021.1899764. Sex Reprod Health Matters. 2021. PMID: 33764856 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
